This site is intended for health professionals only

Addition of tocilizumab to steroids improves survival in those hospitalised with COVID-19

Tocilizumab is licensed for use in rheumatoid arthritis but is also appears to have potentially useful role in those with COVID-19.

Disease progression among those hospitalised with COVID-19 often leads to hypoxic respiratory failure which is associated with systemic inflammation and the release of pro-inflammatory cytokines including interleukin-6 (IL-6). Hypoxic respiratory failure necessitates the use of prolonged ventilatory support and systemic corticosteroids. However, given that the condition is associated with an increased level of pro-inflammatory cytokines, could add-on therapy with immunomodulatory agents such as tocilizumab, which block of IL-6 signally, offer mortality benefits? This is one of the questions being addressed by the randomised evaluation of COVID-19 therapy (RECOVERY) trial which has been established to examine the efficacy of a range of interventions for hospitalised patients infected with the virus. One arm of the study includes the use of tocilizumab. Any patient admitted to hospital because of COVID-19 is eligible for inclusion into the RECOVERY trial if they have either clinically suspected or laboratory confirmed COVID-19 and no medical history which, in the opinion of the treating physician, might put them at a significant risk if they participated in the trial. To be considered for treatment with tocilizumab, patients should have evidence of clinical deterioration of COVID-19 defined by an oxygen saturation less than 92% or receiving oxygen therapy, at which point they are randomised to usual care or tocilizumab as a single intravenous dose (based on the patient’s weight) over 60 minutes. A second dose can be administered the following day, based on the opinion of the treating physician. The primary outcome for the trial is all-cause mortality 28 days after randomisation.

Between April 2020 and January 2021, over 4,000 patients have been recruited into the tocilizumab arm of RECOVERY; 2022 patients with a mean age of 63.6 years (66% male) being assigned to tocilizumab and 2094 to usual care. At the time of randomisation, most patients (45%) in the tocilizumab arm were in receipt of no additional support other than oxygen though 41% required non-invasive respiratory support and the majority (82%) of patients in both groups were already receiving systemic corticosteroids. The interim results demonstrated a significant reduction in mortality among those assigned to tocilizumab compared to usual care (29% vs 33%) and use of the drug was associated with a higher probability of being discharged alive within 28 days (54% vs 47%). Furthermore, among those not on invasive mechanical ventilation at baseline, there was a reduction in the risk of progression to ventilation compared to usual care (33% vs 38%).

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in clinical care at events delivered by renowned experts from CofE

The authors concluded that in patients with severe COVID-19, tocilizumab reduced mortality and the need for invasive mechanical ventilation and that these benefits are additional to the use of systemic corticosteroids.

The RECOVERY Collaborative Group. Tocilizumab for COVID-19. MedRxiv

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine